Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 26Withdrawn 7Unknown 6Terminated 4Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Oxaliplatin 95Fluorouracil 84Capecitabine 75Gemcitabine 72Leucovorin 68Nivolumab 67Bevacizumab 63pembrolizumab 60Magnetic Resonance Spectroscopy 52Specimen Handling 50Irinotecan 50durvalumab 46Radiotherapy 42atezolizumab 40Cisplatin 39Paclitaxel 37Biopsy 37130-nm albumin-bound paclitaxel 34Cetuximab 30Carboplatin 27Albumin-Bound Paclitaxel 26Taxes 24Drug Therapy 20dehydroftorafur 19Radiation 19Ipilimumab 19tislelizumab 18Surgical Procedures, Operative 17Standard of Care 17Docetaxel 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × aflibercept × Gastrointestinal × Clear all
NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
59 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡